Anastasis in Glioblastoma, Brain Cancer Stem, and Brain Stem Cells

Abstract

Objective: Anastasis, a process that has been discovered recently, halts apoptosis, and thus, recovers the survival functions of cells. It may be suggested that anastasis is related to cancer progression, especially in cancer stem cells which are responsible for therapy resistance, metastasis, and recurrence. In this study, the investigation of the anastasis phenomena and its effect on stemness related gene expressions of brain cancer-related cells are aimed. Methods: In this study commercially obtained glioblastoma multiforme(GBM), brain cancer stem cells(BCSC), and brain stem cells(BSC) were used for in vitro models. To induction of apoptosis 4% ethanol-including medium was used. Annexin V assay was used for confirmation of apoptotic and anastatic status. Gene expression profile was determined real-time qRT-PCR method and fold changes were calculated by using 2-∆∆Ct method. Ingenuity Pathway Analysis was used for the functional pathway and upstream regulatory analysis. Results: A common decrease in the expression of stemness related genes in GBM cells was determined by real-time qRT-PCR performed on anastatic cells. Although BSCs showed a similar expression profile with GBM cells, all stemness genes were upregulated in BCSCs. Similar to expression profile, the canonical pathways were markedly down-regulated in BSC and GBM, while they were up-regulated in BCSC. Differently, it is determined that the activation of self-renewal in GBM and BCSC, unlike BSC. Conclusion: We have demonstrated that the inhibition of anastasis may be used to prevent the malignant transformation of healthy stem cells and the aggression of cancerous stem cells. Anastasis may be suggested as a critical mechanism that supports uncurable cancers.

Keywords

• apoptosis
• anastasis
• glioblastoma
• brain stem cell
• brain cancer stem cell
• gene expression

References

1. 1. Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation. 2018; 25(3):486-541. doi:10.1038/s41418-017-0012-4
2. 2. Tang HM, Tang HL. Anastasis: Recovery from the brink of cell death. Royal Society Open Science. 2018;5(9):180442. doi:10.1098/rsos.180442
3. 3. Gudipaty SA, Conner CM, Rosenblatt J, Montell DJ. Unconventional Ways to Live and Die: Cell Death and Survival in Development, Homeostasis, and Disease. Annual Review of Cell and Developmental Biology. 2018 ;34:311-332. doi:10.1146/annurev-cellbio-100616-060748
4. 4. Naik S, Larsen SB, Cowley CJ, Fuchs E. Two to Tango: Dialog between Immunity and Stem Cells in Health and Disease. Cell. 2018;175(4):908-920. doi: 10.1016/j.cell.2018.08.071
5. 5. Takahashi K, Yamanaka S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 2006; 126(4):663-76. doi:10.1016/j.cell.2006.07.024
6. 6. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008; 4(2):68-75. doi:10.4161/org.4.2.5851
7. 7. Kuşoğlu A, Biray Avcı Ç. Cancer stem cells: A brief review of the current status. Gene. 2019;681:80-85. doi:10.1016/j.gene.2018.09.052
8. 8. Sharifzad F, Ghavami S, Mardpour S, et al. Glioblastoma cancer stem cell biology: Potential theranostic targets. Drug Resistance Updates. 2019;42:35-45. doi:10.1016/j.drup.2018.03.003

9. 9. Fiscon G, Conte F, Licursi V, Nasi S, Paci P. Computational identification of specific genes for glioblastoma stem-like cells identity. Scientific Reports. 2018; 8(1):10593. doi:10.1038/s41598-018-26081-5
10. 10. Mazzoldi EL, Pastò A, Pilotto G, et al. Comparison of the Genomic Profile of Cancer Stem Cells and Their Non-Stem Counterpart: The Case of Ovarian Cancer. Journal of Clinical Medicine. 2020; 9(2):368. doi:10.3390/jcm9020368
11. 11. Kuciak M, Mas C, Borges I, Sánchez-Gómez P, Ruiz i Altaba A. Chimeric NANOG repressors inhibit glioblastoma growth in vivo in a context-dependent manner. Scientific Reports. 2019; 9(1):3891. doi:10.1038/s41598-019-39473-y
12. 12. Hu B, Wang Q, Wang YA, et al. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell. 2016;167(5):1281-1295.e18. doi:10.1016/j.cell.2016.10.039
13. 13. Yi Y, Hsieh IY, Huang X, Li J, Zhao W. Glioblastoma stem-like cells: Characteristics, microenvironment, and therapy. Frontiers in Pharmacology. 2016;7:477. doi:10.3389/fphar.2016.00477
14. 14. Wang J, Wang H, Li Z, et al. c-Myc is required for maintenance of glioma cancer stem cells. PLoS ONE. 2008;3(11):e3769. doi:10.1371/journal.pone.0003769
15. 15. Swartling FJ. Myc proteins in brain tumor development and maintenance. Upsala Journal of Medical Sciences. 2012;117(2):122-31. doi:10.3109/03009734.2012.658975
16. 16. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes and Development. 2015; 29(12): 1203–1217. doi:10.1101/gad.261982.115
17. 17. VanderVorst K, Hatakeyama J, Berg A, Lee H, Carraway KL. Cellular and molecular mechanisms underlying planar cell polarity pathway contributions to cancer malignancy. Seminars in Cell and Developmental Biology. 2018; 81:78-87. doi:10.1016/j.semcdb.2017.09.026